35 recruiting. 35 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 35 | Recruiting 35 |
| Phase 1 | 3 | Recruiting 3 |
Follow Asthma: new trials by email Literature Review of Asthma trials Research Report on Asthma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of JNJ-95597528 in Participants With Inadequately Controlled Moderate to Severe Asthma JNJ-95597528, Placebo - Asthma | Phase 2 | Recruiting | Janssen Research & Development, LLC | 440 | 2026-10-05 | 2026-11-03 |
| Rademikibart IV for Acute Asthma and COPD Exacerbation Rademikibart - Asthma Acute, COPD Exacerbation Acute | Phase 2 | Recruiting | Connect Biopharm LLC | 40 | 2026-08-21 | 2026-11-04 |
| Pediatric Asthma Trial of Corticosteroid Heterogeneity (PATCH): Trial of Dexamethasone Versus Methylprednisolone for Pediatric Critical Asthma Dexamethasone (0.6mg/kg; Max 16mg) Once Daily, Dexamethasone (0.25 mg/kg/dose, Max dose 16mg) every 6-hours, Methylprednisolone - Asthma (Diagnosis) | Phase 2 | Recruiting | Johns Hopkins All Children's Hospital | 159 | 2026-08-01 | 2026-08-12 |
| A Clinical Study to Evaluate the Efficacy and Safety of Frevecitinib (KN-002) in Patients With Severe Asthma Frevecitinib, Placebo - Severe Asthma | Phase 2 | Recruiting | Kinaset Therapeutics Inc | 512 | 2026-07-16 | 2026-07-28 |
| A Long-term Study of KT-621 Administered Orally to Participants With Asthma Previously Enrolled in a KT-621 Asthma Study KT-621 - Asthma (Diagnosis) | Phase 2 | Recruiting | Kymera Therapeutics, Inc. | 264 | 2026-06-25 | 2026-10-07 |
| Nebulized Ketamine Plus Standard Care vs. Standard Care Alone in Moderate to Severe Asthma Exacerbations Nebulized ketamine (0.5 mg/kg in normal saline to a total volume of 5ml) plus standard asthma excaerbationcare, Placebo nebulization (5 mL normal saline) plus standard asthma care - Asthma Acute, Asthma Attack | Phase 2 | Recruiting | Oman Medical Speciality Board | 100 | 2026-05-30 | 2026-10-19 |
| Efficacy of L-menthol on Breathlessness in Asthma L-menthol, Placebo - Asthma | Phase 2 | Recruiting | Region Skane | 20 | 2026-05-07 | 2026-08-19 |
| A Phase II Study to Investigate Lung Function With 2 Different Doses of Inhaled Glycopyrronium Taken With BFF Compared to BFF in Participants of 4 to Less Than 12 Years of Age With Asthma GP MDI, BFF MDI, Placebo MDI - Asthma | Phase 2 | Recruiting | AstraZeneca | 69 | 2026-04-14 | 2026-10-13 |
| Study of Inhaled ARO-RAGE in Allergen-induced Mild Asthma ARO-RAGE, Placebo - Asthma | Phase 2 | Recruiting | Arrowhead Pharmaceuticals | 36 | 2026-03-30 | 2026-10-01 |
| VENTURI (VENTilation Using Respiratory Imaging) Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrrolate pMDI, Fluticasone Furoate/Umeclidinium/Vilanterol 100 MCG/1 ACTUATION-62.5 MCG/1 ACTUATION-25 MCG/1 ACTUATION Inhalation Powder - Asthma | Phase 2 | Recruiting | University of Alabama at Birmingham | 20 | 2026-03-15 | 2026-04-13 |
| ENV-294 for Moderate-to-Severe Asthma: A 12-Week Study in Adults ENV-294, Placebo - Asthma | Phase 2 | Recruiting | Enveda Therapeutics | 50 | 2026-01-09 | 2026-09-24 |
| Therapeutic Equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in Subjects With Mild to Moderate Asthma CHF5993 pMDI with HFA-152a, CHF5993 pMDI with HFA-134a, CHF718 pMDI with HFA-134a - Asthma | Phase 2 | Recruiting | Chiesi Farmaceutici S.p.A. | 780 | 2025-12-17 | 2026-06-25 |
| A Clinical Trial of Soluble Fiber for Asthma Inulin - Asthma in Children | Phase 2 | Recruiting | Phoenix Children's Hospital | 105 | 2025-11-10 | 2026-03-04 |
| Study of PRA-216 in Healthy Participants and Participants With Mild-to-Moderate Asthma PRA-216, Placebo - Mild to Moderate Asthma | Phase 1 / Phase 2 | Recruiting | Prana Therapies Inc | 96 | 2025-11-04 | 2026-08-06 |
| A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma Brenipatide, Placebo - Asthma | Phase 2 | Recruiting | Eli Lilly and Company | 531 | 2025-10-22 | 2026-11-05 |
| Study on the Safety and Efficacy of PA9159 Inhalation Aerosol for the Treatment of Adult Bronchial Asthma PA9159 Metered-Dose Inhaler, 120 μg per day for 28 days, Fluticasone Propionate Inhaled Aerosol 200 μg per day for 28 days - Bronchial Asthma | Phase 2 | Recruiting | Anhui Palo Alto Pharmaceuticals, Inc. | 30 | 2025-10-15 | 2026-01-07 |
| Dose-Ranging Study of LQ036 Single-Domain Antibody Nebulization Solution in Poorly Controlled Asthma Placebo, LQ036 - Asthma | Phase 2 | Recruiting | Shanghai Novamab Biopharmaceuticals Co., Ltd. | 216 | 2025-09-30 | 2026-06-25 |
| A Study of HB0056 in Adult Participants With Moderate to Severe Asthma Placebo, HB0056 - Asthma | Phase 1 / Phase 2 | Recruiting | Shanghai Huaota Biopharmaceutical Co., Ltd. | 160 | 2025-08-21 | 2026-10-28 |
| Safety and Immunogenicity of Cat-allergen Intralymphatic Immunotherapy in Patients With Cat Allergy With and Without Asthma ALUTARD SQ® Felis domesticus - Allergic Rhinitis, Allergic Asthma | Phase 1 / Phase 2 | Recruiting | University of Zurich | 36 | 2025-08-20 | 2026-03-16 |
| Study of CM512 Injection in Subjects With Moderate-to-severe Asthma CM512 injection, Placebo - Asthma | Phase 2 | Recruiting | Keymed Biosciences Co.Ltd | 200 | 2025-08-19 | 2025-08-28 |
Showing 20 of 35. Sign in to see all of them.
Lung Diseases (3) · Obesity (3) · Disease (2) · Dyspnea (2) · Hypersensitivity (2) · Respiratory Sounds (2) · Respiratory Tract Diseases (2) · Rhinitis (2) · Rhinitis, Allergic (2) · Airway Obstruction (1) · Bronchial Diseases (1) · Chronic Cough (1) · Cough (1) · Cystic Fibrosis (1)
Hypersensitivity, Immediate (35) · Immune System Diseases (35) · Lung Diseases, Obstructive (35) · Bronchial Diseases (34) · Respiratory Hypersensitivity (34) · Hypersensitivity (33) · Respiratory Tract Diseases (33) · Lung Diseases (32) · Pathological Conditions, Signs and Symptoms (10) · Signs and Symptoms (7) · Signs and Symptoms, Respiratory (4) · Body Weight (3) · Nutrition Disorders (3) · Nutritional and Metabolic Diseases (3) · Overnutrition (3)
Citrulline (2) · Amitriptyline (1) · Beclomethasone (1) · CXA-10 (1) · Dexamethasone (1) · Duloxetine Hydrochloride (1) · Escitalopram (1) · GSK573719 (1) · Glycopyrrolate (1) · Inulin (1) · MAX protein, human (1) · Magnetic Resonance Imaging (1) · Menthol (1) · Methylprednisolone (1) · Saline Solution (1)
University of Colorado, Denver (3) · Anhui Palo Alto Pharmaceuticals, Inc. (2) · AstraZeneca (2) · Arrowhead Pharmaceuticals (1) · Chiesi Farmaceutici S.p.A. (1) · Connect Biopharm LLC (1) · Copenhagen Studies on Asthma in Childhood (1) · Eli Lilly and Company (1) · Enveda Therapeutics (1) · Janssen Research & Development, LLC (1) · Johns Hopkins All Children's Hospital (1) · Johns Hopkins University (1) · Keymed Biosciences Co.Ltd (1) · Kinaset Therapeutics Inc (1) · Kymera Therapeutics, Inc. (1)
United States (21) · China (9) · Argentina (7) · Hungary (5) · Poland (5) · Bulgaria (4) · Germany (4) · Japan (4) · South Africa (4) · Spain (4) · Canada (3) · Czechia (3) · France (3) · Mexico (3) · Serbia (3)
Fernando Holguin, MD, MPH (3) · Wei Zuo (2) · Giles Santyr, PhD (1) · Gurpreet Ahluwalia, PhD (1) · Jakob Stokholm, MD, PhD (1) · Matthew Rank (1) · Meghan Sorondo, PharmD (1) · Meredith C McCormack, M.D., M.H.S. (1) · Michael Wechsler, MD (1) · Omar Khwaja, MD (1) · Ruchong Chen (1)
PMID 28245140, PMID 33303537, PMID 33548468, PMID 35418427
2025 (4), R01HL132550 (1), R01HL146542 (1), R34HL166438 (1), R61HL157069 (1), R61HL167909 (1), U54MD012388 (1)